100 top cell and gene therapy companies to watch in 2023

[Image courtesy of ipopba/Adobe Stock]

The cell and gene therapy sector is poised to deliver a wave of new therapies that could potentially cure rare and common diseases. As many as 13 new cell or gene therapies could be approved for use in the U.S., Europe, or both by the end of 2023.

While manufacturing and regulatory challenges remain, the cell and gene therapy industry continues to offer significant therapeutic potential and commercial opportunities.

This year, we have beefed up our list of leading cell and gene therapy companies, doubling the number of organizations from 50 to 100.

In selecting the companies for this list, we weighed public companies’ degree of involvement in cell and gene therapy, including drug developers, equipment vendors and CDMOs specializing in the area. For private companies, we factored in their funding levels, pipeline and degree of history for the list.


Read more
  • 0

Allogene Therapeutics’ stock drops 46% after FDA puts hold on AlloCAR-T trials

Today, the allogeneic CAR-T company Allogene Therapeutics (NSDQ:ALLO) saw its stock dip to the lowest level since its IPO in 2018.

The company announced that FDA had placed a hold on its AlloCAR T clinical trials after the identification of a chromosomal abnormality in a patient enrolled in its ALPHA2 study (NCT04416984). That trial was a Phase 1/2 study involving 30 patients with relapsed/refractory large B-Cell lymphoma. The study related to the allogeneic CAR-T cell therapy ALPHA2 (ALL0-501A).

“The data generated from our past trials supports a favorable clinical profile for ALL0-501A in patients with large B-cell lymphoma, which underlies our mission to provide allergenic CAR-T therapies, faster and more reliably to patients suffering from some of the most difficult to treat cancers,” said David Chang, president and CEO of Allogene Therapeutics in an investor briefing.

The company stated that its lots of CAR-T cells undergo extensive testing, includi…

Read more
  • 0